Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling by Nindl, Ingo et al.
BioMed  Central
Page 1 of 17
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Identification of differentially expressed genes in cutaneous 
squamous cell carcinoma by microarray expression profiling
Ingo Nindl*1, Chantip Dang1, Tobias Forschner1, Ralf J Kuban2, 
Thomas Meyer3, Wolfram Sterry1 and Eggert Stockfleth1
Address: 1Department of Dermatology, Charité, Skin Cancer Center Charité, University Hospital of Berlin, Charitéplatz 1, D-10117 Berlin, 
Germany, 2Institute of Biochemistry, Charité, University Hospital of Berlin, Monbijoustr. 2, D-10098 Berlin, Germany and 3Institut of Pathology 
and Molecularbiology (IPM), Lademannbogen 61, D-22339 Hamburg, Germany
Email: Ingo Nindl* - ingo.nindl@charite.de; Chantip Dang - chantip.dang@charite.de; Tobias Forschner - tobias.forschner@charite.de; 
Ralf J Kuban - ralf-juergen.kuban@charite.de; Thomas Meyer - meyer@labor-arndt-partner.de; Wolfram Sterry - wolfram.sterry@charite.de; 
Eggert Stockfleth - eggert.stockfleth@charite.de
* Corresponding author    
Abstract
Background: Carcinogenesis is a multi-step process indicated by several genes up- or down-
regulated during tumor progression. This study examined and identified differentially expressed
genes in cutaneous squamous cell carcinoma (SCC).
Results:  Three different biopsies of 5 immunosuppressed organ-transplanted recipients each
normal skin (all were pooled), actinic keratosis (AK) (two were pooled), and invasive SCC and
additionally 5 normal skin tissues from immunocompetent patients were analyzed. Thus, total RNA
of 15 specimens were used for hybridization with Affymetrix HG-U133A microarray technology
containing 22,283 genes. Data analyses were performed by prediction analysis of microarrays using
nearest shrunken centroids with the threshold 3.5 and ANOVA analysis was independently
performed in order to identify differentially expressed genes (p < 0.05). Verification of 13 up- or
down-regulated genes was performed by quantitative real-time reverse transcription (RT)-PCR and
genes were additionally confirmed by sequencing. Broad coherent patterns in normal skin vs. AK
and SCC were observed for 118 genes.
Conclusion: The majority of identified differentially expressed genes in cutaneous SCC were
previously not described.
Background
Nonmelanoma skin cancer (NMSC), encompassing both
basal cell carcinoma (BCC) and squamous cell carcinoma
(SCC), is the most common cancer in Caucasians, and
over the last decade incidence has been increased dramat-
ically worldwide [1]. Actinic keratosis (AK) is an early
stage of SCC and approximately 10% of cases progress to
SCC [2-4]. Ultraviolet radiation (UV) is the major risk fac-
tor for this disease [5,6]. Carcinogenesis is a multi-step
process indicated by a series of genes that are up- or down-
regulated during tumor progression. In normal vs. cancer-
ous colon tissue only 1–1.5% of approximately 30,000 –
50,000 functional genes per cell were differentially
expressed resulting in 548 genes [7]. A comparable quan-
tity was identified in breast cancer cells exhibiting 700
dysregulated genes [8]. Thus, the number of differentially
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expressed genes seem to be similar in different cancers.
Many genes showing increased expression elevated in
colon-cancer represent proteins that are considered to be
involved in growth and proliferation while there were
often attributed to differentiation in normal tissue. Ana-
lyzing skin- or head and neck-cell lines, genes that are
associated with extracellular matrix production and apop-
tosis were disrupted in preneoplastic cells during SCC
development, whereas genes that are involved in DNA
repair or epidermal growth factors were altered at later
stages [9]. Transformation of keratinocytes in response to
UV-radiation was examined by microarray technology
using normal human epidermal keratinocytes and SCC
cell lines [10]. This study detected four clusters of differen-
tially expressed genes in normal keratinocytes vs. skin can-
cer cells, which may play a role in the carcinogenic
pathway. However, cell lines are often different from
human tissues that has been demonstrated for both colon
cancer [11] and ovarian cancer [12,13]. Thus, human can-
cer tissues are superior compared with cell lines analyzing
differentially expressed genes. So far, only one study
examined differentially expressed genes in NMSC tissue
using nylon-filter DNA microarrays analyzing approxi-
mately 7,400 genes [14].
In the present study, we evaluated the different expression
profile of 22,283 genes in normal skin biopsies vs. AK vs.
cutaneous SCC. We focused on dysregulated genes best
characterizing normal skin and NMSC (comprising both
AK and SCC). Overall, 42 genes were up-regulated and 76
genes were down-regulated in skin cancer and the major-
ity of differentially expressed genes were not described
earlier.
Results
Relative expression in normal skin and NMSC
Of the 22,283 transcripts and expressed sequence tags
(EST) investigated on each oligonucleotide microarray,
118 genes were detected differentially expressed in nor-
mal skin, AK, and SCC by Prediction Analysis of Microar-
rays (PAM) analysis excluding 81 genes (EST and genes
with the description "consensus includes...") (see Meth-
ods). For each of the 6 normal skins, 4 AK, and 5 SCC
(Table 1), the relative expression of each gene was exam-
ined. We have controlled the RNA quality of each human
specimen analyzing the fragment sizes, and the ratio of 5'-
and 3'-ends using microarray test-chips with 24 human
control genes of 6 randomly selected specimens and only
non-degraded mRNA specimens were used in this study.
PAM analysis was used to identify genes to classify and to
best characterize normal skin, AK or SCC. The rate of mis-
classification on the basis of individual cross validation
plots was 0% (0.0) for normal skin, 25% (0.25) for AK,
20% (0.20) for SCC, and 13% (0.13) for all three classes.
The first gene list contained 200 genes best characterizing
normal skin (6), AK (4), and SCC (5). Under the exclu-
sion of EST and genes with the description "consensus
includes..." (n = 81) we identified 118 dysregulated genes
(Table 2).
Hierarchical clustering was performed with the identified
118 genes based on similarities of expression levels inde-
pendently of the assigned class (normal skin, AK or SCC).
Gene trees display gene similarities as a dendrogram, a
tree-like structure made up of branches. This nested struc-
ture forces all genes to be related to a certain level, with
larger branches representing the more distantly related
genes (Figure 1). The gene CHI3L1 was detected with two
Table 1: Data of organ transplant (TX) non-melanoma skin cancer (NMSC) patients or non-TX.
Patient Sex/age (years) TX Time after TX 
(years)
Normal skin AK SCC
1 (BN) F/60 Kidney 23 Insight lower arm 
(ILAa)
Finger (1)b Hand (1)
2 (GM) M/66 Kidney 11 ILAa Lower leg (2) Forehead (2)
3 (MP) M/58 Liver 12 ILAa Lower Legc Lower Leg (3)
4 (DR) M/73 Heart 9 ILAa Head (3) Forehead (4)
5 (JG) M/69 Kidney 2 ILAa (1) Earc(4) Forehead (5)
6 (GH) M/57 Non-TX Head (2) NC NC
7 (WM) F/61 Non-TX Cheek (3) NC NC
8 (WM) F/61 Non-TX Head (4) NC NC
9 (EW) F/74 Non-TX Face (5) NC NC
10 (MG) M/17 Non-TX Fundament (6) NC NC
Normal skin, AK, and SCC biopsies were collected from each TX-patient, and in addition normal skin biopsies were obtained from age-matched 
immunocompetent patients (non-TX).
a RNA of 5 normal biopsies were pooled.
b The biopsies used for microarray analysis are indicated with numbers in parentheses marked in bold.
c RNA of 2 AK were pooled.
F, female; M, male; AK, actinic keratosis; SCC, squamous cell carcinoma; NC, not collected.M
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Table 2: Genes identified by Prediction Analysis of Microarrays (PAM) differentially expressed in normal skin compared to non-melanoma skin cancer.
A) Up-regulated genes (42) in non-melanoma skin cancer. Microarray experiments ANOVA
No. Accession No. Symbol Gene Function Localization Change fold 
T/N
Mean of raw 
signal 
(normal)
Mean of raw 
signal 
(AK&SCC)
p-value
Differentiation
1 AF183421.1 rab22b Small GTP-bindung protein 
rab22 (RAB31)
Small GTPase signal transduction. 18p11.3 1.87 6853 12495 n.s.
2 NM_006868.1 RAB31* RAB31, member RAS 
oncogene family
Small GTPase signal transduction. 18p11.3 3.30 2637 8437 0.027
Apoptosis
3 NM_004834.1 MAP4K4* Mitogen-activated protein 
kinase kinase kinase kinase 4
A member of the serine/threonine protein 
kinase family, specifically activate MAPK8/
JNK.
2q11.2-q12 2.65 1475 3898 0.024
Proliferation
4 NM_007375.1 TARDBP TAR DNA binding protein Transcriptional repressor that binds to 
chromosomally integrated TAR DNA and 
represses HIV-1 transcription.
1p36.22 1.48 6779 10441 n.s.
Metabolism
5 D55674.1 hnRNP D Heterogeneous nuclear 
ribonucleoprotein D
Associated with pre-mRNAs in the nucleus 
and appear to influence pre-mRNA 
processing and other aspects of mRNA 
metabolism and transport.
4q21.1-q21.2 1.64 4020 6968 n.s.
6 NM_003942.1 RPS6KA4 Ribosomal protein S6 kinase RSK (ribosomal S6 kinase) family of serine/
threonine kinases
11q11-q13 1.74 3374 6029 0.044
7 NM_001814.1 CTSC Cathepsin C (CTSC) Defects in the encoded protein have been 
shown to be a cause of Papillon-Lefevre 
syndrome, an autosomal recessive disorder 
characterized by palmoplantar keratosis 
and periodontitis.
11q14.1-q14.3 1.64 11435 18686 n.s.
8 Z14077.1 YY1 YY1, NF-E1 protein Transcription factor involved in repressing 
and activating a diverse number of 
promoters.
14q 2.08 4185 8939 n.s.
9 NM_006141.1 DNCLI2 Dynein, cytoplasmic, light 
intermediate polypeptide 2
Involved in retrograde organelle transport 
and some aspects of mitosis.
16q22.1 3.23 2225 5692 n.s.
10 AF061832.1 M4 M4 protein deletion mutant Appear to influence pre-mRNA processing 
and other aspects of mRNA metabolism 
and transport.
19p13.3-p13.2 1.29 11154 14824 n.s.
Cell 
communication
11 U65590 IL-1RN* IL-1 receptor antagonist IL-
1Ra
Inhibits the activities of interleukin 1, alpha 
(IL1A) and interleukin 1, beta (IL1B), and 
modulates a variety of interleukin 1 related 
immune and inflammatory responses.
2q14.2 1.75 9599 18079 n.s.
12 NM_004688.1 NMI* N-myc (and STAT) 
interactor
Interacts with NMYC, CMYC, all STATs 
except STAT2.
2p24.3-q21.3 2.33 2744 6248 n.s.
13 NM_002416.1 MIG Monokine induced by 
gamma interferon
Binding to CXCR3 causes pleiotropic 
effects, including stimulation of monocytes, 
natural killer and T-cell migration, and 
modulation of adhesion molecule 
expression.
4q21 3.54 1492 10529 n.s.
14 U72069.1 TNPO1 Karyopherin beta2 Interacts with nuclear localization signals to 
target nuclear proteins to the nucleus.
5q13.2 2.06 2986 6049 n.s.
15 BC004489.1 HLA-C Major histocompatibility 
complex, class I, C
A central role in the immune system by 
presenting peptides derived from ER 
lumen.
6p21.3 1.30 78196 106054 n.s.M
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16 L42024.1 HLA-B39 MHC, HLA-B39 A central role in the immune system by 
presenting peptides derived from ER 
lumen.
6p21.3 1.35 78040 114101 n.s.
17 NM_005516.1 HLA-E Major histocompatibility 
complex, class I, E
A central role in the immune system by 
presenting peptides derived from ER 
lumen.
6p21.3 1.76 24252 43847 n.s.
18 NM_006096.1 NDRG1 N-myc downstream 
regulated gene 1
Involved in stress responses, hormone 
responses, cell growth, and differentiation.
8q24.3 2.60 17233 44914 0.024
19 AF313468.1 lectin-1 Dendritic cell-associated C-
type lectin-1
Diverse functions, such as cell adhesion, 
cell-cell signalling, glycoprotein turnover, 
and roles in inflammation and immune 
response.
12p12.3-p13.2 3.61 1163 4146 0.019
20 U88964 HEM45 HEM45 HIV-1 Tat upregulates the interferon-
responsive gene expression of HEM45.
15q26 3.24 982 3293 0.019
21 NM_000418.1 IL4R* Interleukin 4 receptor Development of allergic reactions and have 
been shown to modulate the function of 
monocytes and macrophages.
16p11.2-12.1 2.41 2519 6159 0.014
22 NM_015986.1 CREME9 Cytokine receptor-like 
molecule 9
Thought to be involved in signal 
transduction.
17q11.2 1.58 4335 6950 0.015
23 NM_002087.1 GRN* Granulin A role in the development of prostatic 
intraepithelial neoplasia.
17q21.32 1.77 14453 25978 0.034
Adhesion
24 AK023406.1 FLJ13344 FLJ13344 fis High homology to the actin and 
microtubules binding protein ABP620.
1p32-p31 2.49 3656 9107 0.038
25 U03271 CAPZB F-actin capping protein beta 
subunit
Regulates growth of the actin filament by 
capping the barbed end of growing actin 
filaments.
1p36.1 1.35 11809 16060 n.s.
26 NM_005572.1 LMNA Lamin AC Lamin proteins are thought to be involved 
in nuclear stability, chromatin structure 
and gene expression.
1q21.2-q21.3 1.47 13531 19844 n.s.
27 AB010427.2 WDR1 NORI-1 May help induce the disassembly of actin 
filaments.
4p16.1 2.11 7418 15927 <0.001
28 NM_004893.1 H2AFY H2A histone family, member 
Y
A member of the histone H2A family. 5q31.3-q32 1.39 18975 26758 0.048
29 NM_001101.2 ACTB Actin, beta Conserved proteins that are involved in 
cell motility, structure and integrity.
7p15-p12 1.44 120864 178342 0.026
30 NM_000700.1 ANXA1 Annexin A1 Located on the cytosolic face of the plasma 
membrane.
9q12-q21.2 1.74 35910 64023 0.043
31 NM_002160.1 TNC* Hexabrachion (tenascin C, 
cytotactin) (HXB),
Spliced tenascin-C has important roles in 
tumor progression of breast cancer.
9q33 4.60 1819 8694 0.038
32 BF338947 1–8U Interferon induced 
transmembrane protein 3
Transmembrane protein. 11p15.5 1.70 20588 33223 n.s.
33 NM_002421.2 MMP1* Matrix metalloproteinase 1 Involved in the breakdown of extracellular 
matrix in normal physiological processes 
(embryonic development, reproduction, 
and tissue remodeling), in disease 
processes (arthritis, metastasis).
11q22.3 > 10 293 18006 0.024
34 J00269.1 KRT6A Human 56 k cytoskeletal 
type II keratin
Member of the keratin gene family. 12q12-q13 3.79 42604 161154 0.026
35 NM_006825.1 CKAP4 Transmembrane protein Required for cell adhesion. 12q24.11 1.68 12780 22154 0.023
36 NM_005561.2 LAMP1 Lysosomal-associated 
membrane protein 1
Possible a role in tumor cell metastasis. 13q34 1.28 25495 33858 n.s.
37 NM_001793.1 CDH3 Cadherin 3, type 1, P-
cadherin (placental)
Calcium-dependent cell-cell adhesion 
glycoprotein, mutations in this gene have 
been associated with congential 
hypotrichosis with juvenile macular 
dystrophy.
16q22.1 3.63 3819 15934 0.043
38 NM_004360.1 CDH1* Cadherin 1, type 1, E-
cadherin (epithelial)
Calcium dependent cell-cell adhesion 
glycoprotein, mutations in this gene are 
correlated with gastric, breast, colorectal, 
thyroid and ovarian cancer.
16q22.1 1.31 18773 24888 n.s.
Table 2: Genes identified by Prediction Analysis of Microarrays (PAM) differentially expressed in normal skin compared to non-melanoma skin cancer. (Continued)M
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39 BC001920.1 actin gamma Actin, gamma 1 Involved in various types of cell motility, 
and maintenance of the cytoskeleton.
17q25 1.38 108509 152446 n.s.
40 NM_001614.2 ACTG1 Actin, gamma 1 Involved in various types of cell motility, 
and maintenance of the cytoskeleton.
17q25 1.43 113681 166361 n.s.
41 NM_004368.1 CNN2 Calponin 2 Participates in smooth muscle contractio, 
cell adhesion and can bind actin.
21q11.1 1.43 4012 5822 n.s.
42 NM_004994.1 MMP9 Matrix metalloproteinase 9 
(gelatinase B, collagenase)
Involved in the breakdown of extracellular 
matrix in normal physiological processes 
(embryonic development, reproduction, 
tissue remodeling), in disease processes 
(arthritis and metastasis).
20q11.2-q13.1 4.70 3150 16961 n.s.
B) Down-regulated genes (76) in non-melanoma skin cancer. Microarray experiments ANOVA
No. Accession No. Symbol Gene Function Localization Change fold 
N/T
Mean of raw 
signal 
(normal)
Mean of raw 
signal 
(AK&SCC)
p-value
Differentiation
1 NM_004430.1 EGR3 Early growth response 3 Participates in the transcriptional 
regulation of genes in controling biological 
rhythm.
8p23-p21 2.22 7833 3782 n.s.
2 NM_022969.1 FGFR2 Fibroblast growth factor 
receptor 2
Influences mitogenesis and differentiation. 10q26 2.04 9967 5011 n.s.
3 BC001971.1 p27, Kip1 Cyclin-dependent kinase 
inhibitor 1B
Binds to and prevents the activation of 
cyclin E-CDK2 or cyclin D-CDK4 
complexes, and thus controls the cell cycle 
progression at G1.
12p13.1-p12 1.45 8234 5959 n.s.
4 AF309553.1 REC14 Meiotic recombination 
protein REC14
Exact function unknown. Thought to be 
involved in differentiation.
15q24.1 1.96 16148 8395 0.027
5 NM_001424.1 EMP2 Epithelial membrane protein 
2
A role in the control of cell proliferation, 
cell differentiation, and cell death.
16p13.2 2.00 21074 11007 0.026
6 NM_001983.1 ERCC1* Excision repair cross-
complementing rodent 
repair deficiency
Repair protein expression is reduced in 
testis neoplasms.
19q13.2-q13.3 1.79 7222 4073 n.s.
Apoptosis
7 NM_016085.1 APR-3n.s. Apoptosis related protein 
APR-3
Involved in apoptosis, and may also be 
involved in hematopoietic development 
and differentiation.
2p23.3 1.85 21640 11863 0.012
8 AB055804.1 MM-1 beta MM-1 beta Assists in the correct folding of other 
proteins, subunit is thought to repress the 
transcriptional activity of c-myc.
12q12 1.64 35682 22035 n.s.
9 NM_015965.1 CGI-39* CGI-39 protein; cell death-
regulatory protein GRIM19
Signal transducer and activator of 
transcription 3.
19p13.2 1.43 12888 9485 n.s.
Proliferation
10 BC003689.1 HMG 17 High-mobility group (non-
histone chromosomal 
protein 17)
Nucleosomal binding protein. 1p36.1 1.22 46229 38384 n.s.
11 NM_006694.1 JTB Jumping translocation 
breakpoint
Up-regulation in hepatocellular carcinoma 
(HCC).
1q21 1.39 26313 19283 0.030
12 NM_001967.2 EIF4A2 Eukaryotic translation 
initiation factor 4A
Protein translation. 3q28 1.92 41342 22341 0.019
13 NM_005935.1 MLLT2 Myeloidlymphoid or mixed-
lineage leukemia
Interaction with SIAH1 and SIAH2 
proteins, the cell cycle control exerted by 
MLL-AF4 may be responsible of resistance 
to cell-death.
4q21 1.82 14146 8083 n.s.
14 AF279903.1 EC45 60S ribosomal protein L15 A ribosomal protein that is a component of 
the 60S subunit.
3p24.1 1.85 60783 36597 n.s.
Table 2: Genes identified by Prediction Analysis of Microarrays (PAM) differentially expressed in normal skin compared to non-melanoma skin cancer. (Continued)M
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15 NM_002948.1 RPL15 Ribosomal protein L15 A ribosomal protein that is a component of 
the 60S subunit, overexpressed in some 
esophageal tumors compared to normal 
matched tissues.
3p24.1 1.79 79109 46326 n.s.
16 NM_001023.1 RPS20 Ribosomal protein S20 A ribosomal protein that is a component of 
the 40S subunit.
8q12 1.35 78126 58507 n.s.
17 NM_000995.1 RPL34 Ribosomal protein L34 Component of the 60S subunit. 4q25 1.85 92356 52954 n.s.
18 NM_006098.1 GNB2L1 Guanine nucleotide binding 
protein (G protein)
Regulates G1/S progression by suppressing 
Src kinase activity.
5q35.3 1.32 73713 57754 n.s.
19 NM_007104.2 RPL10A Ribosomal protein L10a Downregulated in the thymus by 
cyclosporin-A (CsA), an 
immunosuppressive drug.
6p21.3-p21.2 1.49 77178 54218 n.s.
20 BC000734.1 EIF3S6 Eukaryotic translation 
initiation factor 3
Protein translation. 8q22-q23 1.38 51705 37233 n.s.
21 NM_003756.1 EIF3S3 Eukaryotic translation 
initiation factor 3
Protein translation, overexpression of 
EIF3S3 is associated with breast and 
prostate cancer.
8q24.11 1.49 38725 25795 n.s.
22 BC000524.1 RPS6 Ribosomal protein S6 Protein synthesis, cytoplasmic ribosomal 
protein that is a component of the 40S 
subunit.
9p21 1.23 99499 83221 n.s.
23 NM_001417.1 EIF4B Eukaryotic translation 
initiation factor 4B
Stimulate the nuclease activity of herpes 
simplex virus.
12q13.13 1.35 15184 11509 n.s.
24 NM_000968.1 RPL4 Ribosomal protein L4 Component of the 60S subunit. 15q22 1.30 118180 92600 n.s.
25 NM_015920.1 LOC51065 40S ribosomal protein S27 Similarity with ribosomal protein S27. 15q22.1 1.67 24852 15517 0.043
26 NM_001009.1 RPS5 Ribosomal protein S5 Variable expression of this gene in 
colorectal cancers compared to adjacent 
normal tissues, although no correlation 
between the severity of this disease has 
been observed.
19q13.4 1.54 57497 38110 0.033
27 NM_016091.1 HSPC025 HSPC025 Interacts with Int-6 and is associated with 
eukaryotic translation initiation factor 3.
22q 1.45 58905 41562 0.043
28 L22453.1 TARBP-b HIV-1 TAR RNA binding 
protein (RPL3)
Encodes a ribosomal protein that is a 
component of the 60S subunit; the protein 
can bind to the HIV-1 TAR mRNA, and the 
protein probably contributes to tat-
mediated transactivation.
22q13 1.47 86865 59742 n.s.
29 NM_006013.1 RPL10 Ribosomal protein L10 This gene encodes a ribosomal protein that 
is a component of the 60S subunit.
Xq28 1.27 127604 102770 n.s.
30 NM_014315.1 LCP host cell factor homolog Transcriptional coactivator which 
coordinates the assembly of enhancer 
complex through direct interactions with 
viral and cellular trans-activators.
14q21.3-q22.1 1.92 12588 6756 0.003
Metabolism
31 NM_015958.1 LOC51611 CGI-30 protein Activities of Dipthine synthase, 
methyltransferase, and transferase.
1p21.2 1.67 7739 4726 n.s.
32 NM_000847 GSTA3 Glutathione S-transferase 
A3
Involved in cellular defense against toxic, 
carcinogenic, and pharmacologically active 
electrophilic compounds.
6p12.1 5.00 1557 135 0.005
33 NM_002633.1 PGM1 Phosphoglucomutase 1 Regulatory enzyme in cellular glucose 
utilization and energy homeostasis.
1p31 2.22 22301 10170 0.044
34 BC006229.1 CYC5b Cytochrome c oxidase 
subunit Vb
Terminal enzyme of the mitochondrial 
respiratory chain.
2cen-q13 2.00 17780 9105 0.015
35 NM_001862.1 COX5B Cytochrome c oxidase 
subunit Vb
Terminal enzyme of the mitochondrial 
respiratory chain.
2cen-q13 1.85 26820 14737 0.035
36 NM_002492.1 NDUFB5 NADH dehydrogenase 
(ubiquinone) 1 beta 
subcomplex
A subunit of the multisubunit 
NADH:ubiquinone oxidoreductase 
(complex I).
3q27.1 1.67 18898 11821 n.s.
37 NM_021122.2 FACL2 Fatty-acid-Coenzyme A 
ligase
Plays a role in lipid biosynthesis and fatty 
acid degradation.
4q34-q35 2.50 39142 15864 n.s.
38 BC005270.1 ND4FS4 NADH dehydrogenase 
(ubiquinone) Fe-S protein 4
Multisubunit enzyme complex of the 
mitochondrial respiratory chain, plays a 
vital role in cellular ATP production.
5q11.1 1.85 10920 5956 n.s.
Table 2: Genes identified by Prediction Analysis of Microarrays (PAM) differentially expressed in normal skin compared to non-melanoma skin cancer. (Continued)M
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39 NM_001867.1 COX7C Cytochrome c oxidase 
subunit VIIc
Mitochondrial respiratory chain, catalyzes 
the electron transfer from reduced 
cytochrome c to oxygen.
5q14 2.17 55286 26201 0.013
40 BC003674.1 NDUFA2 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex
Multisubunit enzyme complex of the 
mitochondrial respiratory chain, plays a 
vital role in cellular ATP production.
5q31 1.67 9562 5854 n.s.
41 NM_014402.1 QP-C Low molecular mass 
ubiquinone-binding protein
Activities of oxidoreductase, and ubiquinol-
cytochrome c reductase.
5q31.1 1.69 32210 19064 n.s.
42 BC001917.1 MDH2 Malate dehydrogenase 2, 
NAD (mitochondrial)
Oxidation of malate to oxaloacetate (citric 
acid cycle).
7p12.3-q11.2 1.30 24490 19165 n.s.
43 NM_002489.1 NDUFA4 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex
Multisubunit enzyme complex of the 
mitochondrial respiratory chain, plays a 
vital role in cellular ATP production.
7p21.3 1.59 22038 14006 n.s.
44 NM_005004.1 NDUFB8 NADH dehydrogenase 
(ubiquinone) 1 beta 
subcomplex
Multisubunit enzyme complex of the 
mitochondrial respiratory chain.
10q23.2-q23.33 1.41 25375 18105 n.s.
45 NM_004074.1 COX8 Cytochrome c oxidase 
subunit VIII
Terminal enzyme of the respiratory chain. 11q12-q13 1.37 21360 15941 n.s.
46 NM_004549.1 NDUFC2 NADH dehydrogenase 
(ubiquinone) 1
Multisubunit enzyme complex of the 
mitochondrial respiratory chain.
11q13.4 1.59 33921 21642 n.s.
47 AF042165 COX7CP1 Cytochrome c oxidase 
subunit VIIc
Terminal component of the mitochondrial 
respiratory chain.
13q14-q21 2.08 40375 19940 0.003
48 NM_001861.1 COX4 Cytochrome c oxidase 
subunit IV
Mitochondrial respiratory chain. 16q22-qter 1.25 54196 44561 n.s.
49 L47162.1 FALDH Human fatty aldehyde 
dehydrogenase
Detoxification of aldehydes generated by 
alcohol metabolism and lipid peroxidation.
17p11.2 2.50 16420 6898 0.038
50 NM_000382.1 ALDH3A2 Aldehyde dehydrogenase 3 
family
Detoxification of aldehydes generated by 
alcohol metabolism and lipid peroxidation.
17p11.2 3.33 19513 5867 0.020
51 NM_021074.1 NDUFV2 NADH dehydrogenase 
(ubiquinone) flavoprotein 2
Activities of NADH dehydrogenase, 
electron carrier, and oxidoreductase.
18p11.31-p11.2 1.82 20847 11262 n.s.
52 M22865.1 CYb5 Human cytochrome b5 Cytochrome c oxidase activity. 18q23 3.57 36175 11654 n.s.
53 M22976.1 cyt b5 Human cytochrome b5, 3 
end
Cytochrome c oxidase activity. 18q23 3.70 22288 6090 n.s.
54 NM_001914.1 CYB5 Cytochrome b-5 Cytochrome c oxidase activity. 18q23 3.33 31694 10220 n.s.
55 NM_013387.1 HSPC051 Ubiquinol-cytochrome c 
reductase complex
Activities of oxidoreductase, and ubiquinol-
cytochrome c reductase.
22cen-q12.3 1.43 15592 11200 n.s.
56 NM_001866.1 COX7B Cytochrome c oxidase 
subunit VIIb
Encoded by COX, the terminal component 
of the mitochondrial respiratory chain, 
catalyzes the electron transfer from 
reduced cytochrome c to oxygen.
Xq13.3 1.37 29860 21796 n.s.
57 NM_004541.2 NDUFA1 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex
Codes for an essential component of 
complex I of the respiratory chain, which 
transfers electrons from NADH to 
ubiquinone.
Xq24 2.27 25486 11413 0.026
Cell 
communication
58 BC002669.1 NR2 Nuclear receptor subfamily 
2
Predicted to encode proteins that are very 
similar in primary structure to receptors 
for steroid hormones or thyroid hormone 
(T3).
19p13.1 1.51 7213 4917 n.s.
59 NM_004182.1 UXT Ubiquitously-expressed 
transcript
Interacts with the N-terminus of the 
androgen receptor and plays a role in 
facilitating receptor-induced transcriptional 
activation.
Xp11.23-p11.22 1.59 11609 7489 n.s.
60 M92439.1 LeuP Human leucine-rich protein Activate expression of MDR1 and MVP 
(key components of the cytotoxic defense 
network).
2p21 1.92 6429 3379 n.s.
Adhesion
61 NM_006893.1 LGTN Ligatin A role in neuroplasticity by modulating 
cell-cell interactions, intracellular adhesion, 
and protein binding at membrane surfaces.
1q31-q32 1.70 9444 5566 n.s.
Table 2: Genes identified by Prediction Analysis of Microarrays (PAM) differentially expressed in normal skin compared to non-melanoma skin cancer. (Continued)M
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62 M80927.1 CHI3L1** Human glycoprotein -39 Extracellular matrix structural constituent, 
sugar binding, and hydrolase activity.
1q32.1 7.69 31265 5550 n.s.
63 NM_015717.1 LANGERIN Langerhans cell specific c-
type lectin
Expressed only in Langerhans cells which 
are immature dendritic cells of the 
epidermis and mucosa.
2p13 4.00 4586 1323 0.023
64 NM_007234.2 DCTN3 Dynactin 3 (p22) Involved in a diverse array of cellular 
functions, including ER-to-Golgi transport, 
the centripetal movement of lysosomes 
and endosomes, spindle formation, 
cytokinesis, chromosome movement, 
nuclear positioning, and axonogenesis.
9p13 1.45 13690 9694 n.s.
65 NM_018663.1 LOC55895 Peroxisomal membrane 
protein
Peroxisome organization and biogenesis 
(assembly and arrangement of 
peroxisome).
12q24.33 3.45 6928 2170 n.s.
Detoxification
66 NM_001512.1 GSTA4 Glutathione S-transferase 
A4
Involved in cellular defense against toxic, 
carcinogenic, and pharmacologically active 
electrophilic compounds.
6p12.1 1.41 25838 18009 n.s.
67 NM_004528.1 MGST3 Microsomal glutathione S-
transferase 3
Involved in the production of leukotrienes 
and prostaglandin E, important mediators 
of inflammation.
1q23 1.96 22933 12007 0.023
68 NM_002413.1 MGST2 Microsomal glutathione S-
transferase 2
Catalyzes the conjugation of leukotriene 
A4 and reduced glutathione to produce 
leukotriene C4.
4q28.3 1.82 10888 6065 n.s.
69 NM_015917.1 LOC51064 Glutathione S-transferase 
subunit 13 homolog
Activities of glutathione transferase, 
protein disulfide oxidoreductase, and 
transferase.
7 1.75 9422 5458 n.s.
70 NM_001752.1 CAT Catalase Abnormal expression of catalase in the 
eutopic and ectopic endometrium strongly 
suggests pathologic involvement of free 
radicals in endometriosis and adenomyosis.
11p13 1.61 27669 17923 n.s.
71 L19185 NKEFBn.s. Human natural killer cell 
enhancing factor
Reduce hydrogen peroxide and alkyl 
hydroperoxides.
19p13.2 2.50 39723 17286 n.s.
unknown
72 NM_016098.1 LOC51660 HSPC040 protein Unknown Function. 6q27 3.33 15481 4682 0.038
73 AL356115 KIAA1128 KIAA1128 protein Unknown Function. 10q23.2 1.38 126962 93488 0.048
74 AK022248 FLJ12186 FLJ12186 Unknown Function. 14q22.3 1.38 15261 11116 n.s.
75 NM_004868.1 GPSN2 Glycoprotein, synaptic 2 Unknown Function. 19p13.12 1.69 19830 11888 n.s.
76 AF151056.1 HSPC222 HSPC222 Unknown Function. unknown 1.59 40513 26566 0.030
The accession number, the symbol, the description of the genes, their function, their chromosome localization, the change fold, the raw signal (mean value), and the p values of the ANOVA 
analysis are shown. The accession numbers in bold represent the 42 genes identified by PAM and ANOVA (p < 0.05), which were significantly differentially expressed. The symbols marked in bold 
represent the genes verified by quantitative real-time RT-PCR.
A) Up-regulated genes (42) in non-melanoma skin cancer.
B) Down-regulated genes (76) in non – melanoma skin cancer.
* significant expression difference verified by quantitative real-time RT-PCR.
** positive with two different affymetrix numbers (209395_at and 209396_s_at).
No., numbers; T, Tumor (AK and SCC), N, normal skin; AK, actinic keratosis; SCC, squamous cell carcinoma; n.s., not significant.
Table 2: Genes identified by Prediction Analysis of Microarrays (PAM) differentially expressed in normal skin compared to non-melanoma skin cancer. (Continued)Molecular Cancer 2006, 5:30 http://www.molecular-cancer.com/content/5/1/30
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Cluster map analysis of 118 genes identified by PAM of 15 different specimens resulting in two classes (9 neoplastic skin lesions  and 6 normal skin) Figure 1
Cluster map analysis of 118 genes identified by PAM of 15 different specimens resulting in two classes (9 neo-
plastic skin lesions and 6 normal skin). Prediction Analysis of Microarrays (PAM) using nearest shrunken centroids was 
performed with 22,283 genes, which were present on the microarray platform (Affymetrix) to identify genes best characteriz-
ing normal skin, actinic keratosis (AK), and squamous cell carcinoma (SCC). Hierarchical clustering was performed with 118 
genes identified by PAM (CHI3L1 was detected with two independent Affymetrix probes and are included twice, marked with 
an asterisk). Thirteen genes verified by quantitative real-time RT-PCR are marked in bold. Each color patch represents the nor-
malized expression level of one gene in each group, with a continuum of expression levels from dark blue (lowest) to dark red 
(highest). The minimal set of informative genes is given by HUGO Gene Nomenclature Committee (HGNC) symbols. Group 
(1–9) are non-melanoma skin cancer AK (1, 5, 6, and 8), and SCC (2–4, 7, and 9) showing different expression levels compared 
with six cases of normal skin (10–15). Numbers 6 and 10 were specimens with pooled RNAs.
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different affymetrix numbers and are included twice in the
cluster map (Figure 1). The "Condition Tree" groups sam-
ples together based on similar expression profiles by
standard correlation with the GeneSpring software 6.1
resulting in two classes. The specimens with the pooled
RNA (normal and AK) grouped together with the non-
pooled RNA in class 1 (normal skin) and class 2 (AK and
SCC) (Figure 1). In class 1, all 6 normal skin specimens
grouped together, and class 2 consisted of 4 AK and 5
SCC. Thus, statistical differences in the expression levels
of such genes were not detected in carcinoma in situ (AK)
vs. invasive cancer (SCC). Furthermore, the pooled nor-
mal skin specimens from 5 immunosuppressed patients
grouped together with 5 non-pooled normal skin speci-
mens from immunocompetent patients (Figure 1). Thus,
the expression levels of the selected genes were independ-
ent of systemic immunosuppression.
ANOVA analysis identified 364 genes including 7 EST,
which were significantly differentially expressed between
normal skin, AK, and cutaneous SCC (p < 0.05). Using p
< 0.15 the gene list contained 2,197 genes including 42
EST. The overall agreement rate of the identified genes by
ANOVA using p < 0.05 or p < 0.15 and PAM was 36% (42
of 118) or 78% (92 of 118), respectively. To identify
potentially dysregulated genes between AK and SCC, we
have performed ANOVA analysis in these two groups (p <
0.05), and no gene was significantly differentially
expressed in AK compared with SCC. For further analysis
we have used the 118 genes that have been identified by
PAM and the 42 significantly differentially expressed
genes identified by both methods are highlighted in Table
2.
A higher expression level in skin tumors vs. normal skin
was observed for 42 genes. Of these genes 19 (45%) were
involved in adhesion, 13 (31%) in cell communication, 6
(14%) in metabolism, two in differentiation (5%), and
one each in apoptosis (2%) and in proliferation (2%). In
contrast, a lower expression rate was observed for 76 genes
and 27 (36%) were involved in metabolism, 21 (28%) in
proliferation, 6 (8%) each in differentiation, and detoxifi-
cation, 5 (7%) in adhesion, 3 (4%) each in apoptosis, and
cell communication, and 5 (7%) were of unknown func-
tions.
Verification of selected genes by quantitative real-time RT-
PCR
To verify the different expression levels of mRNA meas-
ured by microarray technology, we selected 13 up- or
down-regulated genes with low through high change folds
from the list of differentially expressed genes. These
included 9 genes with a higher (change folds by micro-
array analysis 1.31 – >10) and 4 with a lower expression
level (change folds by microarray analysis 1.43 – 2.50) in
neoplastic skin lesions vs. normal skin (Table 2). Gene
specific intron-flanking primers were designed for 9 up-
regulated genes (RAB31, MAP4K4, IL-1RN, NMI, IL-4R,
GRN, TNC, MMP1, and CDH1) and 4 down-regulated
genes (ERCC1, APR-3, CGI-39, and NKEFB) (Table 3).
Unspecific PCR products were not obtained for all genes
shown by electrophoresis of the PCR amplicons in agar-
ose gels. Gene-specificity of all 13 genes was confirmed by
sequencing of the PCR product of each gene. The results
of the real-time RT-PCR were consistent with the micro-
array data (Figure 2). All genes showed the predicted
expression level either higher or lower in normal skin vs.
Table 3: Forward and reverse primer sequences for quantitative real-time RT-PCR to verify differentially expressed genes.
Gene Forward (5'-3') Reverse (5'-3')
APR-3 GGT TCT GAT TTC GTC CCT GA CAG CAT TAG CTC TCG TGT CG
CDH1 TGA AGG TGA CAG AGC CTC TGG AT TGG GTG AAT TCG GGC TTG TT
CGI-39 CGT CAA AGG TGA AGC AGG AC ATT ATG CTC CAG TGC CCG TA
ERCC1 GGG AAT TTG GCG ACG TAA TTC GCG GAG GCT GAG GAA CAG
GRN CAG TGG GAA GTA TGG CTG CT TTA GTG AGG AGG TCC GTG GT
IL-1RN GGA AGA TGT GCC TGT CCT GT CGC TTG TCC TGC TTT CTG TT
IL4R CAC CTG CCT CTG TCT CAC TGA A GGC CGC CCA AGT CAT TC
MAP4K4 CTG GTC ACT TGG ATG GTG TG AGA CCG AAC AGA GGC AAA GA
MMP1 CTT GCA CTG AGA AAG AAG ACA AAG G ACA CCC CAG AAC AGC AGC A
NKEFB ACC CAG GAA AGG GCA GAC TTC TAG GTG GAG GCA TTG AGA
NMI GAC ACA CTG CGT GAA GAT CAA TCC AAT CTC CAC AAA CGT GA
RAB31 TGA CCA CAA CAT CAG CCC TA AAT GAA ACC GTT CCT GAC CA
TNC ACT GTG GAC GGA ACC AAG AC TGT GGT GAA TGA CCC TGA GA
RPS9 ATC CGC CAG CGC CAT A TCA ATG TGC TTC TGG GAA TCCMolecular Cancer 2006, 5:30 http://www.molecular-cancer.com/content/5/1/30
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Verification of 13 genes by quantitative real-time RT-PCR Figure 2
Verification of 13 genes by quantitative real-time RT-PCR. Expression levels were based on the amount of the target 
RNA relatively to the endogenous control gene RPS9 in order to normalize the amount and quality of total RNA. Relative 
expression levels of a) 9 up-regulated genes, b) 4 down-regulated genes, and c) 3 up-regulated genes in epithelial skin cancer vs. 
normal skin. c) Three genes were re-analyzed with an increased number of different specimens of immunocompetent and 
immunosuppressed patients (see Methods section 'Patients'). Statistical analysis was performed with the U-Test by Wilcoxon, 
Mann, and Whitney. N, normal skin; T, AK and cutaneous SCC; n.s., not significant; AK, actinic keratosis; SCC, squamous cell 
carcinoma.Molecular Cancer 2006, 5:30 http://www.molecular-cancer.com/content/5/1/30
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skin cancer. The real-time RT-PCR data confirmed signifi-
cant expression differences in 11 of 13 genes (85%) (p <
0.05) (Figure 2). APR-3 and NKEFB showed the predicted
lower expression level in skin tumors vs. normal skin
(median values 0.85 vs. 1.12, p = 0.14, median values 1.0
vs. 2.16, p = 0.11). Furthermore, we reanalyzed 3 of 13
genes with an increased number of specimens of immu-
nocompetent and immunosuppressed patients with nor-
mal skin (n ≥ 21), AK (n = 11), and SCC (n = 15). The
change folds by microarray analysis of the three up-regu-
lated genes MMP1, TNC, and RAB31 were >10, 4.6, and
3.3, respectively. The median expression rate by real-time
RT-PCR in normal skin (N) vs. AK vs. SCC of MMP1 was
0.1 vs. 0.5 vs. 2.9 (N vs. SCC, p ≤ 0.001), of TNC 0.7 vs. 2.1
vs. 14.0 (N vs. SCC, p ≤ 0.001), and of RAB31 0.9 vs. 1.7
vs. 6.3 ((N vs. SCC, p ≤ 0.001), respectively.
Discussion
We have examined the expression levels of 22,283 genes
in human biopsies of normal skin and cutaneous squa-
mous cell carcinoma (AK, and SCC) by microarray tech-
nology. One hundred and eighteen genes were
differentially expressed in normal skin vs. skin cancer and
fulfilled the criteria used for PAM based cluster map anal-
ysis.
Expression profiling using oligonucleotide microarrays is
a useful tool to identify tumors, to distinguish different
tumor entities, and to differentiate between progressing
and non-progressing neoplastic lesions [7,15-18]. In this
study, we used mRNA from skin biopsies without micro-
dissection resulting in high RNA amounts and subse-
quently no amplification of the RNA transcripts were
required. On the other hand, we cannot avoid a mixture
of dysplastic and non-dysplastic cells in our specimens. A
mixture of normal epithelial cells and tumor cells are
most likely present in cancerous lesions (AK) but are
unlikely in normal skin specimens. If the tumor specimen
contained normal and dysplastic cells, an increased gene
expression in cancer vs. normal skin or vice versa was not
detected by microarray analysis. Thus, the number of dif-
ferentially expressed genes detected in our study represent
a subset of all differentially expressed genes in skin cancer
and genes showing only low differences are most likely to
be unidentified.
The number of differentially expressed genes in normal
tissue vs. colon cancer and breast cancer was 548 and 700,
respectively [7,8]. In our study, we detected 118 genes
excluding EST best characterizing normal skin and epithe-
lial skin cancer. These genes represent approximately 20%
of all genes expected to be differentially expressed in skin
cancer. So far, only one study examined the expression
profile in human biopsies of NMSC and skin cancer cell
lines by microarray analyzing approximately 7,400 genes
[14]. Although there was only a minimal overlap between
human tissue and cell lines, five genes were differentially
expressed both in vivo and in vitro, namely fibronectin 1,
annexin A5, glyceraldehyde 3-phosphate dehydrogenase, zink-
finger protein 254, and huntingtin-associated protein interact-
ing protein. Of these genes the calcium and phospholipid-
binding protein annexin 5 was over-expressed (ratio 2.1)
and annexin 1 showed a slightly over-expression in cutane-
ous SCC. In our study using another approach annexin 1
was over-expressed in AK and cutaneous SCC (change fold
1.74) showing that 1 of 5 genes (20%) differentially
expressed in the study of Dooley and colleagues [14]
could be confirmed. Lamin A and C showed a significant
higher expression in AK and SCC compared with normal
skin analyzed by immunohistochemistry [19], and these
genes were also up-regulated in our study. Furthermore,
enzymes of the mitochondrial chain namely cytochrome c
oxidase, cytochrome b, and NADH dehydrogenase were the
majority of down-regulated genes. In prostatic intra-epi-
thelial neoplasia, a high mutation rate of NADH subunits
of the respiratory chain complex I was observed similar to
lung and head and neck cancer [20]. Delsite and col-
leagues [21] examined breast cancer cell lines and sug-
gested that a lack of mitochondrial genes leads to
increased oxidative stress, reduced DNA repair, and
genetic instability. Furthermore, mitochondrial dysfunc-
tion leads to an increased production of reactive oxygene
species (ROS), inhibition of apoptosis, activation of onco-
genes, and inactivation of tumor suppressor genes, and
thus is involved during carcinogenesis [22,23]. In our
study, the majority of these enzymes was down-regulated
in NMSC, indicating that mitochondrial dysfunction is
possible associated with cutaneous SCC.
The reliability of the identified 118 genes by microarray
technology was verified and confirmed by real-time RT-
PCR analyzing 13 genes, and the following discussion is
based on these genes.
9 genes up-regulated in NMSC (CDH1, MAP4K4, IL-1RN, 
IL-4R, NMI, GRN, RAB31, TNC, and MMP1)
CDH1 (E-Cadherin) is a representative of the classic cad-
herin family and a calcium-dependent cell-cell adhesion
glycoprotein, mutations are correlated with a variety of
cancers and loss of function may lead to cancer progres-
sion and metastasis [24]. In our study we observed an
over-expression of CDH1 in skin cancer vs. normal skin,
although a lower expression rate was expected. This may
be due to a wrongly identified gene, a loss of function due
to mutations, a post-transcriptional regulation of this
gene or another mechanism in skin cancer vs. other can-
cers.
MAP4K4 is a representative of the serine/threonine pro-
tein kinase family activating MAPK8/c-Jun N-terminalMolecular Cancer 2006, 5:30 http://www.molecular-cancer.com/content/5/1/30
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kinase (JNK) [25]. JNK signal transduction pathway partic-
ipates in the proliferation, differentiation, and apoptosis
of osteoblasts and is functionally operative in the malig-
nant transformation of osteoblasts and the subsequent
development and progression of human osteosarcomas
[26]. IL-1RN (interleukin 1 receptor antagonist), IL-4R (inter-
leukin 4 receptor), NMI (N-Myc and Stat interactor), and
GRN (granulin) are genes involved in cell communica-
tions.  IL-1RN  is a representative of the interleukin 1
cytokine family inhibiting the activities of IL-1A and IL-
1B, and modulates a variety of interleukin 1 related
immune and inflammatory responses [27]. The
homozygous genotype IL-1RN*2/2 of the IL-RN gene was
strongly associated with early-stage gastric cancer [28]. IL-
4R develop allergic reactions, modulate the function of
monocytes and macrophages and has been shown over-
expressed in a variety of human cancer cells in vitro and in
vivo like melanoma, breast, ovarian, renal, and head and
neck [29]. NMI interacts with the oncogenes C-myc and N-
myc  and other transcription factors containing a ZIP,
HLH, or HLH-Zip motif first isolated and characterized by
Bao and Zervos [30]. In addition, NMI interacts with all
Stats except of Stat2 and augments Stat-mediated tran-
scription in response to cytokines IL-2 and IFN-gamma
[31]. A novel pathogenic mechanism of the transcription
factor complex NMI, BRCA1 and c-Myc is the activation of
telomerase, which is a key enzyme in carcinogenesis [32].
The growth factor GRN stimulates progression and metas-
tasis of breast cancer and is involved in a variety of cancers
such as clear cell renal carcinoma, invasive ovarian carci-
noma and glioblastoma [33]. In our study all 5 genes
showing different functions in tumorigenesis were also
over-expressed in skin cancer.
Rab31 represent a family of monomeric GTP-binding pro-
teins and belongs to the Ras family [34,35]. Ras is a proto-
oncogene, which is evolutionary conserved and is
involved in various cancers [36], but the precise role of
Ras, especially Ha-ras in NMSC is unknown. TNC is an
extracellular matrix protein with anti-adhesive effects, and
involved in tissue interactions during fetal development
and oncogenesis. TNC  was associated with breast and
lung cancer [37] and was over-expressed in vulvar intraep-
ithelial neoplasia. Matrix metalloproteinases (MMP) are
involved in extracellular matrix degradation and cancer
invasion [38,39]. Tsukifuji and colleagues [40] reported
an over-expression of MMP-1, MMP-2, and MMP-3 in skin
cancer (16 Ak, 6 AK with SCC, and 15 SCC). We detected
an increased expression rate of MMP-1 and MMP-9 in skin
cancer and both genes showed the highest expression rate
in AK/SCC indicated by the change-folds of MMP-1 (<10),
and MMP-9 (4.70) by microarray analysis. All three genes
are considered to be involved in a variety of cancers, they
were over-expressed in our study and may play a role in
the cancerogenesis of NMSC, and thus are interesting can-
didates for further studies.
4 genes down-regulated in NMSC (ERCC1, APR-3, CGI-
39, and NKEFB)
ERCC1 has a high homology with the yeast excision repair
protein RAD10 [41], is reduced in testis neoplasms [42]
and ovarian cancer cell lines [43]. APR-3 is considered to
be involved in apoptosis and was identified using subtrac-
tive hybridization strategy in order to clone apoptosis-
related genes [44]. NKEFB encodes a representative of the
peroxiredoxin (Prx) family of antioxidant enzymes and
may play a role in cancer development [45]. Prx II was
strongly expressed in mature endothelial cells of benign
vascular tumors, whereas it was weakly or not expressed in
immature endothelial cells in malignant tumors of
Kaposi's sarcoma and angiosarcoma [46]. In our study
these genes were also down-regulated in skin cancer, and
thus were consistent with the expected expression level
observed in other carcinoma.
Conclusion
In conclusion, we identified 42 genes up-regulated and 76
genes down-regulated in cutaneous squamous cell carci-
noma (AK and SCC) vs. normal skin, which represent
approximately 20% of the genes differentially expressed
in skin cancer. The majority of genes which known func-
tions in other cancers was consistent with our results of
differentially expressed genes in NMSC. These 118 genes
either individually or more likely together or a subset of
these genes may prove useful for diagnostic approaches.
Methods
Patients
Biopsies were obtained from 5 organ-transplanted (TX)
recipients (3 kidney, 1 heart, and 1 liver, 58–73 years,
median age 66 years) each normal skin, AK, and SCC. The
time since transplantation ranged from 2 through 23 years
(median 11 years), and no rejection was observed. All
patients had multiple NMSC, such as AK, SCC and/or
basal cell carcinoma, and lesions were mainly located on
sun-exposed areas. The specimens from TX recipients of 5
normal skin and 2 AK specimens were pooled due to the
low RNA amount of the individual specimens that was
not sufficient for further microarray analyses. Further-
more, we have included 5 normal skin specimens from
age-matched non-immunosuppressed individuals (17–74
years, median age 61 years). Thus, we have analyzed 6
normal skin, 4 AK, and 5 SCC specimens by microarray
technology (Table 1). All clinical specimens were col-
lected under standardized conditions by the same clini-
cian (TF). From each organ-transplanted patient, punch
biopsies (diameter 4 mm) of normal tissue, AK, and SCC
were collected. Half of the tissue was transferred to liquid
nitrogen within 2 minutes of resection and stored at -Molecular Cancer 2006, 5:30 http://www.molecular-cancer.com/content/5/1/30
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70°C until RNA isolation was performed. The other half
of each biopsy was fixed in formalin, embedded in paraf-
fin and sections were stained with hematoxylin and eosin
for histological evaluation. All clinical diagnoses, normal
skin, AK, and SCC were confirmed by histology.
The same 15 RNA specimens (or representative subsets)
were used for quantitative real-time reverse transcription
(RT)-PCR of 13 selected genes for verification (Figure 2).
Furthermore, 3 of these 13 genes MMP1, RAB31, and TNC
were additionally examined by real-time RT-PCR with dif-
ferent specimens. For this analysis we used specimens of
22 normal skin (50–79 years, median age 63 years,
including one immunosuppressed patient), of 11 AK (55–
83 years, median age 63 years, including 7 immunosup-
pressed patients), and of 15 SCC patients (46–84 years,
median age 61 years, including 7 immunosuppressed
patients). The RNA amount of one normal skin specimen
was not sufficient for TNC analysis, reducing the number
of samples from 22 to 21 in this analysis. The study was
approved by the local ethics committee at the Charite,
University Hospital, Berlin, Germany (number Si. 248).
RNA isolation and microarray hybridization
Total RNA was isolated using a modified RNeasy Micro Kit
protocol (Qiagen, Hilden, Germany). The modification
included the homogenization of the frozen tissue in 300
μl of buffer RLT (Qiagen) with 20 ng Glycogen (Roche,
Mannheim, Germany) using a rotar-stator homogenizer
"Ultra Turrax T25" (Janke & Kunkel, Staufen, Germany).
The homogenized tissue was digested with 10 μl Protein-
ase K (10 mg ml-1) (Roth, Karlsruhe, Germany) at 55°C
for 15 min. Subsequently the sample was digested with
DNase I (Invitrogen, Karlsruhe, Germany). Quantifica-
tion of isolated RNA was performed using UV-spectros-
copy and the quality was determined both by A260/A280
ratio and Agilent bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA). Five microgram total RNA was
used for cDNA synthesis with 5 pmol μl-1 T7-oligo(dT)24
primer and was performed at 43°C for 90 minutes with
the "Superscript First-Strand Synthesis-System" for RT-
PCR (Invitrogen). Second-strand synthesis was performed
with complete cDNA. The cDNA solution was incubated
at 16°C for 2 hours followed by an incubation step for 20
min with 6 U T4-DNA polymerase at 16°C and the reac-
tion was stopped using 10 μl of 0.5 M EDTA. The double
stranded cDNA was purified by phenol/chloroform, etha-
nol precipitated and the pellet was resuspended in 12 μl
of DEPC water. Labeled cRNA was generated from the
cDNA sample by an in vitro transcription reaction that was
supplemented with biotin-11-CTP and biotin-16-UTP
(Enzo Diagnostics, Farmingdale, NY, USA) according to
the manufacturer. The cRNA was quantified by A260, and
the quality was determined using the labchip bioanalyzer
(Agilent). Only cRNA specimens with a high quality were
selected for further analyses. Fragmented cRNA (15 μg)
was used to prepare 300 μl hybridization cocktail (100
mM MES, 1 M NaCl, 20 mM EDTA, 0.01% Tween-20)
containing 0.1 mg ml-1 of herring sperm DNA, and 0.5 mg
ml-1 acetylated bovine serum albumine. Control cRNA
was used in order to compare hybridization efficiencies
between arrays and to standardize the quantification of
measured transcript levels and was included as compo-
nent of the 'Eukaryotic Hybridization Control kit'
(Affymetrix, Santa Clara, CA, USA). The cocktails were
heated to 95°C for 5 minutes, equilibrated at 45°C for 5
minutes, and clarified by centrifugation. The cocktail was
hybridized to HG U133A arrays (Affymetrix) at 45°C for
16 hours. The arrays were washed and stained with a
streptavidin-conjugated fluor using the GeneChip fluidics
station protocol EukGE-WS2 (Affymetrix) according to
the manufacturer's instructions. Arrays were scanned with
an argon-ion laser confocal scanner (Hewlett-Packard,
Santa Clara, CA) with detection at 570 nm. Data were
extracted using Microarray Suite version 5.0 (Affymetrix)
and linearly scaled to achieve an average intensity of
2,500 per gene. Text files were exported to determine the
intensity of each interrogating oligonucleotide perfect
match probe cells or mismatch probe cells. In addition,
the ratios of 5'- and 3'-ends of mRNA were analyzed of six
randomly selected specimens (two of each group) using
microarray test-chips (Test3 Array) containing 24 human
housekeeping/maintenance genes (Affymetrix) and RNA
degradation was not observed.
Bioinformatic analysis
The Data Mining Tool 3.0 (Affymetrix) and GeneSpring
software package 6.1 (Silicon Genetics, Redwood City,
CA, USA) were used for different replicates and statistical
analyses were performed in order to compare between
cancer stages. For each hybridization, the intensities were
normalized in three steps, (1) data transformation, (2)
per chip, and (3) per gene. (1) All values below 300 were
set to 300, (2) each chip was normalized to the 50th per-
centile of the measurements, and (3) the median of the
intensities of each probe sets representing one gene of all
15 microarray experiments was taken. The normalized
values were used for further analyses.
All processings from raw data, normalized raw data and p-
detection values of the microarray experiments to the final
tables and figures and a description of the method are pro-
vided as supplemental material with the series number
GSE2503 [47]. Thus, the entire process of analysis is com-
pletely transparent and the description of the methodol-
ogy used is according to the MIAME standard (minimum
information about a microarray experiment).
We used PAM for classification of tumors and identifica-
tions of genes that were significantly different expressedMolecular Cancer 2006, 5:30 http://www.molecular-cancer.com/content/5/1/30
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between three groups. PAM is a statistical technique for
class prediction from gene expression data using nearest
shrunken centroids. The technique has advantages in
accuracy, especially when more than two classes are con-
sidered to be examined [48,49] as it is required for this
study. PAM ranks genes using a panelized t-statistic and
uses soft-thresholding to identify a gene set for classifica-
tion. Data analysis was performed with 22,283 genes of all
15 specimens depending on their class (normal skin, AK,
or SCC). The number of genes used was controlled by a
thresholding parameter, which was determined with a 10-
fold cross-validation. We used the imputation engine
method with the k-nearest neighbor (n = 10), and the
threshold 3.5 was chosen to minimize the overall error
rate. This cross validation also allows a judgment of the
classification quality. For the detailed mathematic proce-
dure, see Tibshirani et al. [48].
In addition, we have independently applied the ANOVA
model using two different p-values (p < 0.05 and p < 0.15)
to identify dysregulated genes between three groups (nor-
mal skin, AK, and SCC) and two groups (AK and SCC) to
focus on differences between these two groups. Multiple
testing corrections were performed by the false discovery
rate of Benjamini and Hochberg for all analyses.
Hierarchical clustering was performed with the genes best
characterizing normal skin and NMSC identified by PAM.
Genes of all 15 specimens with different expression pro-
files were grouped by standard correlation with Gene-
Spring software package 6.1. Hierarchical clustering of the
genes was based on similarities of expression levels.
Quantitative real-time RT-PCR
Real-time RT-PCR with the LightCycler system (Roche)
was used as an independent method to validate the micro-
array expression data and to assess quantitative gene
expression. Thirteen genes were selected including 9 up-
regulated and 4 down-regulated genes in NMSC with low,
moderate, and high change folds. In addition, 3 of the 13
genes (MMP1, RAB31, and TNC) were verified with an
increased number of different specimens of immunosup-
pressed and immunocompetent patients (22 normal skin,
11 AK, and 15 SCC) (see Methods section 'Patients'). RT
was performed with the "Superscript First-Strand Synthe-
sis-System" (Invitrogen) using oligo-dT as described by
the manufacturer. The concentration of cDNA was quan-
tified with "OliGreen ssDNA Quantitation Kit" (Molecu-
lar Probes, Leiden, Netherlands). Specific PCR primers for
the target genes were designed using the Primer3 software
program [50], and synthesized by Metabion (Planegg-
Martinsried, Germany). The primers of each gene were
located in different exons to exclude DNA contamination.
Amplification mix (20 μl) contained 20 ng of cDNA, 500
nM of each primer, 2 μl LightCycler FastStart Reaction Mix
Syber Green I (Roche), 3 mM MgCl2 and sterile double
distilled water. The concentration of MgCl2  varied
depending on each specific primer pair between 3–5 mM.
PCR reaction was initiated with 10 min denaturation at
95°C followed by 40 cycles (95°C for 10 sec, 60°C for 5
sec, and 72°C for 10 sec). Fluorescence detection was per-
formed immediately at the end of each annealing step and
the purity of each amplification product was confirmed by
generating melting curves. All specific RT-PCR products of
target genes were purified by gel extraction and confirmed
by sequencing with gene specific primers (Table 3) using
the DNA sequencing kit and the ABI PRISM 310 Genetic
Analyzer (Applied Biosystems, Foster City, USA). A nega-
tive control without reverse transcriptase was included in
each PCR experiment. The expression of RPS9 was used to
control equal RNA loading and to normalize relative
expression data for all other genes analyzed. The copy
ratio of each analyzed cDNA was determined as the mean
of two experiments. The U-Test of Wilcoxon, Mann, and
Whitney was applied for estimation of differentially
expressed transcripts identified by real-time RT-PCR. A p-
value < 0.05 was considered significant for alpha.
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